Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2021 | Transplantation with alternative donors in myelofibrosis

Nicolaus Kröger • 4 Mar 2021
EBMT 2021
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Myelofibrosis

Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, compares outcomes for patients with myelofibrosis, acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), who receive transplantation with an alternative donor. Prof. Kröger reports that an HLA-identical sibling is still the preferred donor for patients with myelofibrosis. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

More from Nicolaus Kröger

1:23
COSTEM 2023: congress highlights and importance
Nicolaus Kröger • 21 Oct 2023
0:35
The importance of bridging therapy in follicular and mantle cell lymphoma
Nicolaus Kröger • 28 Oct 2022
1:31
CAR-T therapy versus autoSCT in DLBCL
Nicolaus Kröger • 28 Oct 2022
0:51
The need for disease-modifying drugs in myelofibrosis
Nicolaus Kröger • 28 Oct 2022

Related Videos

4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals